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We report a successful treatment with voriconazole (VRCZ) for chronic progressive pulmonary asper-
gillosis (CPPA) in a patient with dermatomyositis-associated interstitial lung disease (DM-ILD) treated
with tacrolimus. A 73-year-old man with DM-ILD, treated with tacrolimus and prednisolone, complained
of productive cough and his chest X-ray showed inﬁltration in the left upper lung ﬁeld. We diagnosed
CPPA and added VRCZ. Although we reduced the dose of tacrolimus for drug interaction, serum VRCZ
level increased after the treatment. The patient was found to have cytochrome P450 (CYP) 2C19 *2/*2, a
genetic polymorphism in poor metabolizers of VRCZ. We adjusted the doses of both drugs and treated
him successfully. We recommend performing individual therapeutic drug monitoring (TDM) in CYP-
mediated drug interactions and considering the effect of CYP polymorphisms.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tacrolimus is a calcineurin inhibitor that selectively suppresses
T lymphocytes secreting inﬂammatory cytokines [1]. It has been
adopted for the treatment of collagen vascular disease. Recent re-
ports have showed that concomitant use of tacrolimus and pred-
nisolone was beneﬁcial for interstitial lung disease complicated
with polymyositis or dermatomyositis [2,3]. However, opportu-
nistic infections frequently occur in patients with polymyositis or
dermatomyositis under the use of immunosuppressants. In
particular, Aspergillus species is one pathogen involved in pulmo-
nary infection [4].
Voriconazole (VRCZ), a triazole antifungal medication, has been
shown to be effective as primary or salvage therapy for subacute
invasive and chronic pulmonary aspergillosis [5]. This drug is
metabolized by cytochrome P450 (CYP) 2C19, 2C9, and 3A4. Thehiku, Hamamatsu 431-3125,
ashi).
Ltd. This is an open access article ugenetic polymorphisms of CYP2C19 in the Japanese have been
known higher frequency than that in other races, and poor
metabolizers of VRCZ [6e8]. Besides, VRCZ elevates serum levels of
tacrolimus, mainly metabolized by CYP3A4 [1], as a result of
competitive inhibition of CYP3A4 [9e11]. However, there are a few
reports about this drug interaction, and the optimal treatment of
tacrolimus and VRCZwith CYP2C19 polymorphism has not yet been
determined.
This case report is a valuable report that actually identiﬁed the
genetic polymorphism of CYP2C19 for successful treatment of
chronic progressive pulmonary aspergillosis (CPPA) [12]. We
describe a case of CPPA treated with VRCZ in a patient receiving
tacrolimus, and discuss the drug interaction between tacrolimus
and VRCZ in patients with CYP2C19 polymorphisms.2. Case report
A 73-year-old man weighting 63 kg had complained of facial
ﬂushing, occipital rash, and pain in his shoulder and thigh. He had a
medical history of diabetes and autoimmune hemolytic anemia. Ander the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 2. Clinical course. The abbreviations used are: PSL; prednisolone, FK506; tacroli-
mus, VRCZ; voriconazole. Solid line indicates serum concentration of FK506. Dotted
line indicates serum concentration of VRCZ.
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myalgia, and arthralgia. Laboratory studies showed elevated serum
creatine kinase levels with no autologous antibodies (anti-amino-
acyl tRNA synthetase including anti-Jo-1). Myositis was found in
muscle biopsy. Chest computed tomography showed interstitial
pneumonia. We diagnosed the patient as having dermatomyositis
with interstitial lung disease. Treatment with tacrolimus and
prednisolone after methylprednisolone pulse therapy was initially
commenced. After improvement of disease, the maintenance dose
was 4 mg/day of tacrolimus and 12.5 mg/day of prednisolone. He
subsequently complained of productive cough and his chest X-ray
showed inﬁltration in the left upper lung ﬁeld 8 months after the
initial treatment (Fig.1a). The chest computed tomography ﬁndings
showed wall thickening and inﬁltrative shadows around the cavity
(Fig. 1b) and blood examination revealed slight elevation of white
blood cell count (10,370/mL) and C-reactive protein (1.39 mg/dL).
Liver and kidney function test were within the normal rage
(aspartate transaminase 13 U/L, alanine transaminase 10 U/L, blood
urea nitrogen 15.7 mg/dL, creatinine 0.84 mg/dL). Levels of creatine
kinase, Krebs von den Lungen-6, and surfactant protein-D were not
elevated. (1,3)-b-D-glucan was <0.6 pg/mL and antigens for
Aspergillus, Candida, and Cryptococcus were negative. However, the
anti-Aspergillus antibodywas positive. Furthermore, the percentage
of neutrophils in bronchoalveolar lavage was elevated (15.4%), and
pathological examination of the transbronchial biopsy revealed
alveolitis without fungus. No pathogen was detected in sputum or
bronchial lavage ﬂuid culture. We treated the patient with 6 g/day
of sulbactam/ampicillin with no symptomatic improvement for 7
days. As a result, we diagnosed clinical CPPA by continuous respi-
ratory symptom over a month, pre-existed cavities and peri-
cavitary progressive inﬁltrates in the left upper lobe, anti-Asper-
gillus antibody detection, elevation of inﬂammatory markers, and
antibiotics ineffectiveness [12,13]. We began treatment with
600 mg/day of oral VRCZ followed by a 400 mg/day maintenance
dose, and also halved the dose of tacrolimus, because the drug
interaction with VRCZ had been reported [9e11]. We had per-
formed therapeutic drug monitoring (TDM) during follow-up
(Fig. 2). On the 4th day after treatment with VRCZ, we reduced
the tacrolimus dose to 1 mg/day because of the high trough
tacrolimus level (10.7 ng/mL, optimal trough levels 5e10 ng/mL).
On the 14th day, the trough concentration was still elevated
(11.8 ng/mL) so we further reduced the dose of tacrolimus to
0.6 mg/day. Although a previous report showed that serum VRCZ
concentration was barely affected by tacrolimus [9e11], in our
patient the level of VRCZ gradually increased. The serum concen-
tration of VRCZ was 2.21 mg/mL on the ﬁrst measurement andFig. 1. Chest radiograph showing areas of inﬁltrative shadows in the left upper lung ﬁeld (a)
appearance of inﬁltration around the cavity (b).increased maximum 4.01 mg/mL on the 17th day (appropriate
concentration 1e4 mg/mL). The liver enzymes were elevated
simultaneously (aspartate transaminase 118 U/L, alanine trans-
aminase 101 U/L). We examined the genetic polymorphism of
CYP2C19 using the GENECUBE® (TOYOBO, Fukui, Japan) [14], was a
fully automated rapid genetic analyzer, with the informed consent
of the patient and the CYP2C19 *2/*2 allele was found. We reduced
the dose of VRCZ to 200 mg/day. The serum levels of VRCZ
decreased to 2.31 mg/mL and his liver dysfunction improved
(aspartate transaminase 17 U/L, alanine transaminase 16 U/L). The
trough concentration of tacrolimus decreased to 6.0 ng/mL on the
hospital discharge. The chest X-ray revealed improvement of
inﬁltration around the cyst wall (Fig. 3). His symptoms resolved
after treatment with VRCZ, and his dermatomyositis has remained
stable.3. Discussion
VRCZ is mainly metabolized by CYP2C19 in the liver. There are
three metabolizer types: extensive metabolizer, heterologous
extensive metabolizer, and poor metabolizer (PM) of VRCZ
depending on the genetic CYP2C19 polymorphism. The frequency
of PM varies among racial groups. For example, the percentage of
PM in Japan is about 18e23%, which is higher than that in other. Computed tomography scan of the chest showing the wall of the cavity thickening and
Fig. 3. Chest radiograph showing improvement of inﬁltration around the cyst wall in
the left upper lung ﬁeld after treatment with voriconazole.
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VRCZ gradually increased. Thus we hypothesized that the patient
was a PM of VRCZ by the CYP2C19 polymorphism, and performed
gene analysis. We identiﬁed the patient as a homozygote of
CYP2C19 *2/*2, a PM of VRCZ. Concerning CYP2C19 polymorphisms,
two genetic defects are responsible for the majority of the poor
metabolizers of this enzyme. These variants are two null alleles,
which include a splice defect in exon5 (CYP2C19 *2; trivial name,
m1; single base change G/A) and a premature stop codon at po-
sition 636 of exon 4 (CYP2C19 *3; trivial name, m2; single base
change G/A), while CYP2C19 *1 represents the wild-type allele
[8]. We suggest that impaired metabolism of VRCZ leads to an
elevation its concentration in serum. Therefore CYP3A4, a common
enzyme of VRCZ and tacrolimus, was more strongly inhibited and
the serum level of tacrolimus further increased. This supports our
hypothesis that the mere reduction of VRCZ dose decreased the
tacrolimus concentration after the dose of tacrolimus was ﬁxed.
The drug interaction between VRCZ and tacrolimus has been
recognized, with VRCZ increasing serum tacrolimus concentration
via competitive inhibition of CYP3A4 [9e11,15]. Other azole anti-
fungals have been known to have the drug interaction involving
CYP enzymes. VRCZ has lower inhibitory potency on CYP activity
than ketoconazole and itraconazole, and similar to ﬂuconazole [16].
Tacrolimus has a narrow therapeutic window and adverse events
such as nephrotoxicity can occur depending on blood concentra-
tion. The physician prescribing information for tacrolimus recom-
mends reducing the tacrolimus dose to one-third on initiating
VRCZ, followed by TDM [17]. However, this reduction in tacrolimus
dose may not be sufﬁcient, and there are limited data about dose
reduction of tacrolimus on starting VRCZ. A strategy for adjustment
of tacrolimus dose has not yet been determined. In our case, we
preemptively halved the dose of tacrolimus and continued TDM of
tacrolimus.
Triﬁlio et al. initially reduced tacrolimus dose by 30% when
administered concomitantly with VRCZ. The tacrolimus dose was
ultimately reduced between 60 and 80% on amg/kg basis compared
with baseline dosing using a preemptive, two-step dose-reduction
strategy for 16 days [10]. Conversely, Mori et al. reported that the
concentration/dose (C/D; (ng/mL)/(mg/kg)) ratio was useful for the
quantitative evaluation of drug interaction, reﬂecting both the
concentration and dose of tacrolimus [11,15]. They showed that the
median C/D ratio of tacrolimus changed from 172.8 with a range of
28.6e1110.7 (ng/mL)/(mg/kg) to 537.5 with a range of 127.8e1933.3(ng/mL)/(mg/kg) after adding VRCZ. Median increase of the C/D
ratio was 138.8% (range 32.0 to 685.7%) [15]. In our case, the ﬁnal
tacrolimus dose reduction was 85%. The C/D ratio changed from
65.3 to 1009.9 (ng/mL)/(mg/kg), an increase of 1546.6%. Both the
dose reduction and increase in C/D ratio were higher than in pre-
vious reports [10,11,15]. Although serum VRCZ concentration is
reportedly unaffected by co-administration of tacrolimus [9e11],
we found that a poormetabolizer of VRCZ increased the serum level
of VRCZ and resulted in higher concentration of concomitant
tacrolimus.
In conclusion, we describe a case of CPPA treated with VRCZ in a
patient receiving tacrolimus. The drug interaction and gene poly-
morphism of CYP enzymes resulted in simultaneous adjustment of
the doses of tacrolimus and VRCZ. We should consider performing
individual TDM in CYP-mediated drug interactions and take care
when reducing doses of co-administered drugs.Conﬂict of interest
The authors declare that they have no conﬂict of interest.References
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